In line with these results, we have previously shown that 5-(N-Ethyl-N-Isopropyl)amiloride (EIPA), a specific NHE1 inhibitor [76], modulates uptake of matrigel, collagen I and CDMs generated by normal and cancer-associated fibroblasts [5]. The gene discussed is SLC9A1; the disease is cancer.